Daxor Corporation (NASDAQ:DXR) Short Interest Update

Daxor Corporation (NASDAQ:DXR) saw a significant growth in short interest during the month of August. As of August 31st, there was short interest totaling 592 shares, a growth of 93.5% from the August 15th total of 306 shares. Currently, 0.0% of the company’s shares are short sold. Based on an average daily volume of 3,474 shares, the days-to-cover ratio is currently 0.2 days.

Hedge Funds Weigh In On Daxor

Large investors have recently modified their holdings of the stock. Crescent Grove Advisors LLC bought a new position in Daxor in the 1st quarter worth about $104,000. Nano Cap New Millennium Growth Fund L P purchased a new position in Daxor in the 4th quarter worth approximately $184,000. Empirical Financial Services LLC d.b.a. Empirical Wealth Management bought a new position in Daxor in the 1st quarter valued at approximately $245,000. Susquehanna International Group LLP boosted its stake in Daxor by 97.7% during the 2nd quarter. Susquehanna International Group LLP now owns 27,131 shares of the company’s stock valued at $275,000 after purchasing an additional 13,411 shares during the last quarter. Finally, Aristides Capital LLC bought a new stake in shares of Daxor in the 1st quarter worth $403,000. Hedge funds and other institutional investors own 1.34% of the company’s stock.

Daxor Stock Down 1.1%

Shares of Daxor stock traded down $0.13 during trading on Thursday, hitting $11.59. The company’s stock had a trading volume of 2,789 shares, compared to its average volume of 10,800. Daxor has a 52 week low of $8.56 and a 52 week high of $14.76. The company has a fifty day simple moving average of $10.48 and a two-hundred day simple moving average of $10.42.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reissued a “hold (c)” rating on shares of Daxor in a research report on Wednesday, June 24th. One investment analyst has rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy”.

Daxor Company Profile

Daxor Corporation is a medical device company that develops and commercializes diagnostic technologies for measuring blood volume. Its primary product is the BVA-100 Blood Volume Analyzer, which uses an automated tracer-dilution technique to measure a patient’s total blood volume, red blood cell volume and plasma volume.

The BVA-100 is designed to support clinical assessment and management in areas such as heart failure, critical care, blood disorders and other conditions in which a patient’s fluid or blood-volume status is important.